date,title,source
Nov-05-18,Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options,Zacks
Nov-05-18,Data Collected by Exalenz Bioscience in Galectin Therapeutics Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting,GlobeNewswire
Nov-13-18,Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update,GlobeNewswire
Nov-19-18,Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit,GlobeNewswire
